TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00281580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Description: Telmisartan 40 mg once daily for eight weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 mg
Description: amlodipine 5g once daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Description: Amlodipine 5 mg once daily for eight weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Description: Telmisartan 40 mg once daily for eight weeks
Study: NCT03713086

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabipur®
Description: 3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
Study: NCT00281580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Description: Telmisartan 80 mg once daily for eight weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10 mg
Description: Amlodipine 10 mg once daily for six weeks
Study: NCT03780387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Felis Catus
Description: Inhalation of Felis Catus allergen in subjects allergic to Felis Catus
Study: NCT02919345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Dapagliflozin 10 mg in addition to Metformin 1500 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide 5 mg
Description: Glibenclamide 5 mg in addition to Metformin 1500 mg/day
Study: NCT02111356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phinhole glasses
Description: Wearing the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
Study: NCT02786511

Intervention type: DRUG
Intervention: Safety and efficacy assessments
Description: Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
Study: NCT03924076

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UHT Milk + Lactobacillus plantarum IS-10506
Description: 125 ml UHT milk (+Lactobacillus plantarum IS-10506) given to treatment group

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: UHT Milk
Description: 125 ml UHT milk given to placebo group
Study: NCT03713086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies mRNA vaccine CV7202
Description: CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies mRNA vaccine CV7202
Description: CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies mRNA vaccine CV7202
Description: CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
Study: NCT04354363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: Giving women PRP before ICSI
Study: NCT02949739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle modification
Description: The intervention is delivered as 9 face-face and 13 telephone contact sessions over 12 months. Index cases are the focus for the intervention, but lifestyle modification encourages the whole family to adopt healthy living.
Study: NCT03343535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Lung Preservation
Description: OCS Lung Preservation
Study: NCT02749266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustment
Description: Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham chiropractic adjustment
Description: Participants will receive a simulated chiropractic adjustment with a handheld adjusting instrument called an Activator.
Study: NCT01271166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
Study: NCT00225758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1500 mg po daily for 26 weeks or longer
Study: NCT01514435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Description: treatment for major depression

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18-Fluoro-desoxy-glucose positron emission tomography
Description: intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.~It´s a neuroimaging technique.
Study: NCT01259024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization using a drug-eluting bead
Description: Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
Study: NCT01104298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
Study: NCT00564070

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual plus adherence training
Description: The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced treatment as usual plus CBT-AD
Description: The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
Study: NCT03522259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 MG Oral Tablet [Xarelto]
Description: Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 10 MG Oral Tablet [Xarelto]
Description: Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)
Study: NCT01169259

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.
Study: NCT04275479

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose Tolerance Test
Description: This is a two step process. Subjects will be asked to fast overnight,(no food and only water to drink for at least 8 hours). Then when subjects arrive for the visit,participants will have blood drawn and be asked to drink a sugary liquid. One hour later, another blood sample will be drawn and after two hours a final blood sample will be drawn.

Intervention type: OTHER
Intervention: Modified Oral Glucose Tolerance Test
Description: The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). There will be no blood drawn during this test, participant will be asked to drink a sugary liquid and to remaining fasting (water only) for the two hour after finishing the drink.

Intervention type: OTHER
Intervention: Modified Mixed Meal Tolerance Test
Description: The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). The participant will be given a meal supplement to drink in place of breakfast, for example Boost Plus. The participant will be asked to drink the meal supplement and to remaining fasting (water only) for the next two hours.

Intervention type: OTHER
Intervention: Modified Mixed Meal Tolerance Test
Description: The participant will be asked to fast overnight (no food and only water to drink for at least 8 hours). The participant will be given a meal supplement to drink in place of breakfast, for example Boost Plus. The participant will be asked to drink the meal supplement and to remaining fasting (water only) for the next two hours.

Intervention type: DEVICE
Intervention: Continuous Glucose Monitor
Description: The participant will be provided a CGM device to wear for 10 days during the study period. The CGM will be blinded (meaning that the participant will not be able to see the results).

Intervention type: DEVICE
Intervention: Continuous Glucose Monitor
Description: The participant will be provided a CGM device to wear for 10 days during the study period. The CGM will be blinded (meaning that the participant will not be able to see the results).

Intervention type: OTHER
Intervention: Food Diary
Description: The participant will be asked to maintain a detailed food diary for 3 days during the 10 day study period.

Intervention type: OTHER
Intervention: Food Diary
Description: The participant will be asked to maintain a detailed food diary for 3 days during the 10 day study period.

Intervention type: OTHER
Intervention: Medical History Questionnaires
Description: The participant will be asked to provide detailed medical history

Intervention type: OTHER
Intervention: Medical History Questionnaires
Description: The participant will be asked to provide detailed medical history
Study: NCT00835575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg (Orally Disintegrating) Tablets
Description: 1 x 15 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REMERON SolTab® 15 mg Orally Disintegrating Tablets
Description: 1 x 15 mg, single-dose fasting
Study: NCT00302146

Intervention type: DRUG
Intervention: 15-0 H20

Intervention type: DRUG
Intervention: 15-0 H20

Intervention type: DRUG
Intervention: 15-0 H20
Study: NCT00663663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Delivered Intervention 1
Description: Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Delivered Intervention 2
Description: Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
Study: NCT00137254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: IV insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stable Isotopes
Description: IV administration of stable isotopes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Description: IV administration of ICG
Study: NCT00840398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BUSPAR® 30 mg Tablet
Description: 1 x 30 mg, single-dose fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone Hydrochloride 30 mg Tablet
Description: 1 x 30 mg, single-dose fed
Study: NCT00151229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: target blood pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: target blood pressure
Study: NCT02203760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib plus Gemcitabine
Description: Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
Study: NCT01683045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Estech COBRA® Surgical System
Description: The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
Study: NCT01342939

Intervention type: OTHER
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: 50g waterfree glucose dissolved in 300ml water consumed over 5 min.

Intervention type: OTHER
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: 50g waterfree glucose dissolved in 300ml water consumed over 5 min.

Intervention type: OTHER
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: 50g waterfree glucose dissolved in 300ml water consumed over 5 min.
Study: NCT02203760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Pazopanib 800 mg orally once daily
Study: NCT01342939

Intervention type: OTHER
Intervention: iso glycaemic intravenous (iv) glucose infusion (IIGI)
Description: 20% glucose

Intervention type: OTHER
Intervention: iso glycaemic intravenous (iv) glucose infusion (IIGI)
Description: 20% glucose

Intervention type: OTHER
Intervention: iso glycaemic intravenous (iv) glucose infusion (IIGI)
Description: 20% glucose

Intervention type: DIETARY_SUPPLEMENT
Intervention: Meal test
Description: Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Meal test
Description: Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Meal test
Description: Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)

Intervention type: OTHER
Intervention: Sitagliptin
Description: Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones

Intervention type: OTHER
Intervention: Incretin effect on sulphonyl urea treatment
Description: Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.

Intervention type: OTHER
Intervention: Incretin effect on sulphonyl urea treatment
Description: Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
Study: NCT03292458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oxybate
Description: Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.
Study: NCT04684186

Intervention type: PROCEDURE
Intervention: Endovascular fiducial marker insertion
Description: Fiducial markers will be inserted using an endovascular route

Intervention type: PROCEDURE
Intervention: Bronchoscopic fiducial marker insertion
Description: Fiducial markers will be inserted using an endoscopic route
Study: NCT02280863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Hybrid Closed-loop System - Android Platform
Description: A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Hybrid Closed-loop Integrated System
Description: A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Hybrid Closed-loop Integrated System
Description: A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm
Study: NCT01326494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1 Oral Cortico Steroids
Description: Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )
Study: NCT03461380

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Menopause Relief EP-40
Description: Fixed combination of black cohosh and Rhodiola rosea

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Black Cohosh
Description: 6.5 mg black cohosh

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Black Cohosh
Description: 500 mg black cohosh

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 600 mg excipient
Study: NCT00581607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosentan
Description: drug given for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01327781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxifen Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01383122

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed electromagnetic field device (ActiPatch TM)
Description: Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive pulsed electromagnetic field device (ActiPatch TM)
Description: Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
Study: NCT02367612

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented milk
Description: Fermented milk with Lactobacillus paracasei CBA L74

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT02263365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
Study: NCT02435628

Intervention type: OTHER
Intervention: Questionnaires
Description: All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
Study: NCT03078517

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
Study: NCT01327781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02492919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medixair®
Description: Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
Study: NCT02974426

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PORT-first
Description: PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PORT-last
Description: PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
Description: Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
Description: Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
Study: NCT02717715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home base stroke rehabilitation
Description: The intervention consists of physiotherapy exercises targeting functional and physical capacity.
Study: NCT03307070

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for individuals with TBI
Description: Cognitive Behavioral Therapy for depression that has been adapted for a population who has experienced a moderate to severe Traumatic Brain Injury. This is a 12 week long treatment for depression with weekly visits that challenges negative thoughts and behaviors. This version has been specifically developed for the study to account for specific cognitive needs of individuals who have experienced a moderate to severe TBI.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Participants will be randomized to a waitlist. They will attend biweekly study sessions for 12 weeks to track progress, but will receive their treatment as usual.
Study: NCT01362270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Acupuncture
Description: DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days